Advertisement
Advertisement
JANX
Janux Therapeutics, Inc. Common Stock
18.03
USDSponsored
-0.75
-3.99%
Aug 28, 16:00 UTC -4
Closed
After-Market
18.02
-0.02
-0.08%
JANX Earnings Reports
Positive Surprise Ratio
JANX beat 15 of 21 last estimates.
71%
Next Report
Date of Next Report
Nov 04, 2026
Estimate for Q3 26 (Revenue/ EPS)
$7.90M
/-$0.48
Implied change from Q2 26 (Revenue/ EPS)
-23.05%
/+37.14%
Implied change from Q3 25 (Revenue/ EPS)
-20.99%
/+23.08%
Janux Therapeutics, Inc. Common Stock earnings per share and revenue
On Aug 06, 2026, JANX reported earnings of -0.35 USD per share (EPS) for Q2 26, beating the estimate of -0.39 USD, resulting in a 10.71% surprise. Revenue reached 10.27 million, compared to an expected 16.82 million, with a -38.97% difference. The market reacted with a -1.55% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 15 analysts forecast an EPS of -0.48 USD, with revenue projected to reach 7.90 million USD, implying an increase of 37.14% EPS, and decrease of -23.05% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Alvotech Ordinary Shares
Report Date
Aug 19, 2026 For Q2 26
Estimate
-$0.02
Actual
-$0.11
Surprise
-300.00%
Immatics N.V. Ordinary Shares
Report Date
Aug 18, 2026 For Q2 26
Estimate
-$0.43
Actual
-$0.46
Surprise
-5.70%
Prenetics Global Limited Class A Ordinary Share
Report Date
Aug 18, 2026 For Q2 26
Estimate
-$0.71
Actual
-$0.53
Surprise
+26.30%
Clinuvel Pharmaceuticals Limited - ADR
Report Date
Aug 27, 2026 For Q4 26
Estimate
$0.50
Actual
-Surprise
-
Anavex Life Sciences
Report Date
Aug 25, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+1.96%
Molecular Partners AG - ADR
Report Date
Aug 25, 2026 For Q2 26
Estimate
-Actual
-$0.35
Surprise
-
Chemomab Therapeutics Ltd. - ADR
Report Date
Aug 19, 2026 For Q2 26
Estimate
-$0.15
Actual
-$0.24
Surprise
-56.86%
EVOGENE LTD.
Report Date
Aug 18, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.14
Surprise
+49.16%
FAQ
What were Janux Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Janux Therapeutics, Inc. Common Stock reported EPS of -$0.35, beating estimates by 10.71%, and revenue of $10.27M, -38.97% below expectations.
How did the market react to Janux Therapeutics, Inc. Common Stock's Q2 2026 earnings?
The stock price moved down -1.55%, changed from $16.10 before the earnings release to $15.85 the day after.
When is Janux Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 04, 2026.
What are the forecasts for Janux Therapeutics, Inc. Common Stock's next earnings report?
Based on 15
analysts, Janux Therapeutics, Inc. Common Stock is expected to report EPS of -$0.48 and revenue of $7.90M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement